Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 08:20PM GMT
Release Date Price: €20.68 (+0.05%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. Thanks for joining us. Pleased to have the Denali team with us. We have Ryan Watts, CEO, Co-Founder and President; and Alex Schuth, CFO and COO.

Ryan, to start here, you've made steady progress with the pipeline, notably with positive data from Hunter Syndrome with your blood brain-barrier portfolio, and we saw some data at World Symposium recently. As you look to second half onwards, where do you see the most important areas that investors should focus to understand the value proposition for the story?

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Well, thank you for having us here again, Salveen. And yes, it's been a lot of steady progress. In fact, we founded Denali 7 years ago. And I think what's most exciting for us right now is that we have 6 clinical stage programs, and 3 of them are entering late-stage efficacy studies or have entered within the last several months. And I think that just shows the early

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot